Targeting the Immune System with Plant Lectins to Combat Microbial Infections

Jannyson J. B. Jandú,1,† Roberval N. Moraes Neto,2,† Adrielle Zagmignan,2 Eduardo M. de Sousa,2 Maria C. A. Breilaz-de-Castro,3 Maria T. dos Santos Correia,1 and Luís C. N. da Silva2,*

Author information Article notes Copyright and License information Disclaimer

This article has been cited by other articles in PMC.

Abstract

Introduction

Through centuries, microbial infectious diseases continue to be among the leading causes of mortality and morbidity worldwide (Morens and Fauci, 2013; Sands et al., 2016; Rogalski et al., 2017). No doubt, the antibiotics discovery in the 1930s has revolutionized medicine and changed the treatment of infectious diseases, resulting in a dramatic increase in life expectancy and quality (Aminov, 2016). However, ever since these drugs were introduced, microbial resistance has evolved and spread very rapidly (Davies and Davies, 2010). Indeed, eukaryotic and prokaryotic microbes can acquire drug resistance by several mechanisms [for review see (Van Acker et al., 2014; Blair et al., 2015; Fairlamb et al., 2016; Goncalves et al., 2016; Hall and Mah, 2017)]. This fact critically reduces the shelf life of antibiotics that are not efficient to combat the emerging multidrug-resistant strains (Holmes et al., 2016; Laxminarayan et al., 2016). In addition, pathogens have developed several mechanisms to evade and suppress the host defenses and/or to induce exacerbated inflammation (which may cause host tissue injury) (Chaves et al., 2016; Gomes et al., 2016; Ko, 2016; Malachowski et al., 2016; Sha et al., 2017). This scenario encourages the development of new approaches to treat microbial infection, such as those based on the modulation of the host immune system. The immunomodulatory therapies are based in the stimulation of specialized and specific host immune responses against microbes rather than target microbe viability or virulence (Hancock et al., 2012; Czaplewski et al., 2016; Fura et al., 2017).

Among the natural products, plant lectins are known as potent immunomodulatory agents, able to act in both innate and adaptive immune system. They modulate the production of...
cytokines and other mediators of immune response (such as reactive oxygen and nitrogen species), and, thus, improve the defenses against microbes (Souza et al., 2013; da Silva and Correia, 2014; Coelho et al., 2017). Plant lectins comprise one heterogeneous class of proteins with at least one non-catalytic carbohydrate-binding domain (Coelho et al., 2017). The lectin–carbohydrate interactions have been associated with several biotechnology applications (Komath et al., 2006; de Oliveira Figueiroa et al., 2017). In several cases, the immunomodulatory activity of plant lectins was associated with their interaction with glycan moieties present on the surface of immune cells. Such interaction can result in signal transduction which triggers the effector mechanisms involved in the response against microbial infections (Souza et al., 2013).

Plant lectins play a crucial role in the protection against microbial phytopathogens (Hwang and Hwang, 2011; Kim et al., 2015). Based on this, the antimicrobial and antivirulence actions of several lectins have been demonstrated in vitro against different bacteria of medical importance, as reviewed by several authors (Islam and Khan, 2012; Dias Rde et al., 2015; Coelho et al., 2017; Palharini et al., 2017). Other works have demonstrated the antibacterial effects of lectins using in vitro cell-based assays. For example, a lectin isolated from Aegle marmelos fruit inhibited the adherence and invasion of Shigella dysenteriae to human colonic epithelial cells (HT29 cells), protecting these cells against cell death (induced through apoptosis) (Raja et al., 2011). Similarly, the chitin-binding lectin isolated from the juicy sarcotesta of Punica granatum (named PgTel) showed to have broad-spectrum antibacterial action (inhibiting Gram-positive and Gram-negative bacteria). PgTel was also able to inhibit the invasion of some bacteria to HeLa cells (human epithelioid cervix carcinoma) (Silva et al., 2016b).

The immunomodulatory effects of plant lectins on different immune cells have been also addressed by several authors (Unitt and Hornigold, 2011; Pereira-da-Silva et al., 2012; Souza et al., 2013; da Silva and Correia, 2014; Coelho et al., 2017). Based on this, some works have demonstrated that some well-known immunomodulatory lectins are able to enhance the phagocytic ability of immune cells and their cytokine production in the presence of bacteria (da Silva et al., 2015b; Batista et al., 2017). This review aims to highlight the use of immunomodulatory plant lectins in contending infection provoked by bacterial, fungal, and protozoan pathogens. The lectins selected for this review did not exhibit direct inhibition of microbial growth (using in vitro assays), thus their in vivo actions are related to their ability to target the immune system. Initially, these in vivo studies were primarily focused on mouse models of infection and are summarized in Table 1.

| Table 1 |
| --- |
| Application of immunomodulatory lectins in in vivo experimental models of microbial infections. |
| Lectin | Plant species | Sugar specificity | Pathogen              | Type of use | Reference                  |
|--------|---------------|-------------------|-----------------------|-------------|----------------------------|
| Artin M| *Artocarpus*   | Mannose           | *Candida albicans*    | Prophylactic| Custodio et al., 2011      |
|        | *integrifolia*|                   |                       |             |                            |
|        | *Paracoccidioides* |                 | *Candida albicans*    | Prophylactic| Custodio et al., 2011      |
|        |               |                   |                       |             |                            |
|        |               |                   | *Paracoccidioides*     | Therapeutic | Coltri et al., 2008        |
|        |               |                   | *brasiliensis*        |             |                            |
|        | *Leishmania*  | Adjuvant          | *Paracoccidioides*     | Adjuvant    | Panunto-Castelo et al., 2001; Teixeira et al., 2006 |
|        | *spp.*        |                   |                       |             |                            |
|        | *Toxoplasma*  | Therapeutic       | *Paracoccidioides*     | Therapeutic | Santana et al., 2014       |
|        | *gondii*      |                   | *brasiliensis*        |             |                            |
|        | *Neospora*    | Adjuvant          | *Paracoccidioides*     | Adjuvant    | Cardoso et al., 2011       |
|        | *caninum*     |                   | *brasiliensis*        |             |                            |
| CFL    | *Cratylia*    | Glucose/mannose   | *Salmonella*           | Prophylactic| Silva et al., 2016a        |
|        | *argentea*    |                   | *enterica*            |             |                            |
|        | *ConA*        | Mannose           | *Klebsiella*           | Prophylactic| Kuo et al., 2007          |
|        | *Canavalia*   |                   | *pneumoniae*          |             |                            |
|        | *ensiformis*  |                   |                       |             |                            |
|        | *Candida*     | Prophylactic      | *Klebsiella*           | Prophylactic| Kuo et al., 2007          |
|        | *albicans*    |                   | *pneumoniae*          |             |                            |
|        | *Lovola et al., 2002; Moresco et al., 2002 | | | | | |
| Lectin | Plant species       | Sugar specificity | Pathogen                  | Type of use | Reference                  |
|--------|---------------------|-------------------|---------------------------|-------------|----------------------------|
| ConBr  | *Canavalia brasiensis* | Glucose/mannose   | *Salmonella enterica*     | Prophylactic | Silva et al., 2016a        |
| Cramoll| *Cratylia mollis*    | Mannose           | *Cryptococcus gattii*     | Therapeutic | Jandú et al., 2017         |
| Jacalin| *Artocarpus integrifolia* | Galactose       | *Trypanosoma cruzi*       | Adjuvant    | Albuquerque et al., 1999   |
|        |                     |                   | *Neospora caninum*        | Adjuvant    | Cardoso et al., 2011       |
| ScLL   | *Synadenium carinatum* | Galactose        | *Leishmania amazonensis*  | Prophylactic | Afonso-Cardoso et al., 2011|
|        |                     |                   | *Neospora caninum*        | Adjuvant    | Cardoso et al., 2012       |
|        |                     |                   | *Toxoplasma gondii*       | Therapeutic | Santana et al., 2014       |

Plant Lectins to Combat Bacterial Infections

As mentioned before several papers have investigated the potential of plant lectins direct inhibit bacterial growth (Souza et al., 2013; da Silva and Correia, 2014; Coelho et al., 2017), however, only few experimental studies are available about their in vivo effects (as illustrated in Figure11). These lectins are well known due to their ability to modulate the host immune system.
FIGURE 1
Schematic representation of studies employing plant lectins in experimental bacterial infection. (A) After inoculation, bacteria can invade cell and provoke damage by releasing different virulence factors and inducing an exacerbated immune response. The final effect is organ dysfunction and animal death. (B) Administration of a lectin (for example, ConA) after infection could improve mice response against bacterial infection and increase the animal survival. (C) Pre-treatment of animal with lectin (such as ConBr) induces an immune response able to protect against bacterial virulence resulting in the improvement of animal survival. The proteins structures were obtained from Protein Data Bank, the ID codes are 4PF5 and 4P14 for ConA and ConBr, respectively.

Benefits of Prophylactic and Therapeutic Treatments with Concanavalin A in Klebsiella pneumoniae Infection

The most studied plant lectin is Concanavalin A (ConA) which is isolated from Canavalia ensiformis. ConA is able to stimulate the proliferation of immune cells and enhance the expression of toll-like receptors (Sodhi et al., 2007; da Silva and Correia, 2014). In order to evaluate whether ConA immunomodulatory properties could inhibit a bacterial infection, a murine model based on intragastrical inoculation of Klebsiella pneumoniae was employed (Kuo et al., 2007). K. pneumoniae is a pathogen commonly associated with nosocomial infections that can invade tissues provoking damage on
essential organs (such as liver necrosis) and sepsis (Wu et al., 2017). Although ConA had no effect on the in vitro bacterial growth, beneficial effects were observed when infected mice were submitted either to prophylactic or therapeutic treatment with this lectin. The pretreatment (2 h before infection) with single doses of ConA (1 mg/kg or 2 mg/kg) enhanced the mice survival to 55% after 9 days of infection (the survival rate for untreated infected mice was 10%). When ConA (2 mg/kg) was administered in consecutives doses (2 h before infection followed by other doses at 48 and 96 h), the animal survival rate was 83% (the best effect observed in this study). The last treatment was based on the administration of two successive doses at 24 or 72 h after infection, resulting in a 50% of mice survival for ConA at 2 mg/mL. The effects of ConA were further demonstrated by the inhibition of liver necrosis induced by K. pneumoniae, reduced levels of aspartate aminotransferase and alanine aminotransferase, and bacterial survival in blood and liver (Kuo et al., 2007).

ConBr and CFL Have Prophylactic Effects on Salmonella enterica Infection

Recently, the prophylactic effects of the lectins isolated from Canavalia brasiliensis (ConBr) and Cratylia argentea (CFL) were evaluated in an experimental model of Salmonella enterica serovar Typhimurium infection (Silva et al., 2016a). Both lectins were previously reported as immunomodulatory agents (de Oliveira Silva et al., 2011). Firstly, the authors showed that these lectins did not have anti-S. enterica activity in concentrations ranging from 0.019 to 10,000 μg/mL. Afterward, each lectin was inoculated into Swiss mice (intraperitoneal route; i.p.) at different concentrations (1, 5, and 10 mg/kg) 1 day prior bacterial infection (i.p.). Both lectins showed a 70–80% dose-dependent survival rate increase effect after 7 days of treatment, for ConBr and CFL, respectively. When the lectins were administered (at 10 mg/kg) daily for 3 days prior to bacterial infection (i.p. route), the survival ratios were 90% for CFL and 100% for ConBr. The authors also showed reduction of bacterial growth into the peritoneal cavity, bloodstreams, spleen, and the liver of lectins pre-treated animals. Furthermore, both lectins reduced the amounts of TNF-α and IL-10 cytokines in the peritoneal fluid, but IL-1 was only reduced using ConBr (Silva et al., 2016a). In a later paper, these lectins were shown to inhibit the colonization of Swiss mice peritoneal macrophage by Salmonella, through modulation of the expression of TLR and inflammatory mediators (cytokines and nitric oxide) (Batista et al., 2017).

Plant Lectins for Treatment of Fungal Infections

Despite the use of antifungal agents, the invasive fungal infections are responsible for high rates of morbidity and mortality (Badiee and Hashemizadeh, 2014; Camplesi et al., 2017; Enoch et al., 2017). For example, cryptococcosis is responsible for 1 million cases of meningoencephalitis, especially in HIV positive individuals, with 624,000 death per year (McMullan et al., 2013). Yeasts from Candida genus, particularly Candida albicans, are commonly found as etiological agent of neonatal bloodstream infections (Fu et al., 2017; Vaezi et al., 2017).

Other example is the neglected disease paracoccidioidomycosis, the most important systemic mycosis in Latin America (mainly in Brazil) with high mortality rates (de Macedo et al., 2016). In fact, paracoccidioidomycosis is the eighth most important cause
of mortality among chronic infectious diseases, reaching rates of 1.65 deaths per 106 inhabitants (de Oliveira et al., 2015). Collectively, these invasive fungal infections are more prevalent in immunocompromised patients (Woyciechowsky et al., 2011; Kaur et al., 2017; Sungkanuparph et al., 2017). In addition, they are in general also associated with antifungal resistance, making their treatment ineffective for most cases (Gullo et al., 2013; Chowdhary et al., 2014; Scorzoni et al., 2017).

Taken together, these factors point out the need of studies, using both in vitro and in vivo models, for the development of new therapeutic alternatives to treat fungal infections. In this scenario, lectins with immunomodulatory compounds have been emerging as promising options (Armstrong-James and Harrison, 2012; Datta and Hamad, 2015). Cytokines, antibodies, opsonins, and immunomodulatory compounds (combined or not with antifungals drugs) are therapeutic alternatives for the treatment of fungal infections (Armstrong-James and Harrison, 2012; Datta and Hamad, 2015; Posch et al., 2017; Scorzoni et al., 2017), such as cryptococcosis (Antachopoulos and Walsh, 2012), invasive Candida infections (Safdar et al., 2004), and aspergillosis (Stuehler et al., 2011). In fungal infection models, large number of lectins have been applied in vitro and in vivo in order to develop new antifungal strategies (Islam and Khan, 2012; Coelho et al., 2017). Some examples of plant lectins able to modulate fungal infections are provided below.

**ConA Pretreatment Protects Mice from *Candida albicans* Infection**

The effects of ConA in an experimental model of *C. albicans* infection have been associated with activation of antifungal responses by increasing of phagocytosis and killing of yeast cells by macrophages and neutrophils (Loyola et al., 2002; Moresco et al., 2002). However, the literature does not describe any direct effects of ConA on *C. albicans* viability or virulence. In the first paper, by Loyola et al. (2002), ConA was intraperitoneally administrated and, after 6 h, the collection of neutrophils and macrophages from peritoneal exudate was performed. ConA administration increased the number of peritoneal cells and their in vitro ability to kill *C. albicans* (in both yeast and germ tube forms) and increased the expression of mannose receptors. Furthermore, ConA pre-treatment also increased the survival of animals challenged with *C. albicans* (6 h after the lectin inoculation) (Loyola et al., 2002). These data were confirmed by a similar work where ConA efficiently promoted the antifungal action of peritoneal macrophages from suckling and adult mice by increasing the phagocytosis and killing of *C. albicans*. This paper also showed that ConA protected suckling mice against intraperitoneal infection with *C. albicans* (Moresco et al., 2002).

**Artin M Has Prophylactic and Therapeutic Effects on Fungal Infections**

The mannose-specific lectin present in *Artocarpus integrifolia* (Moraceae) seeds, nominated Artin M, is a well-known immunomodulatory protein able to stimulate neutrophils migration by haptotaxis (Ganiko et al., 2005; Souza et al., 2013). This capacity is due to its interaction with mannose residues, commonly found at extracellular matrix components (such as laminin), helping the cell migration into injured tissues. This is an important phenomenon in the inflammatory response against infections (Ganiko et al., 2005; Souza et al., 2013). *A. integrifolia* seeds are also sources of jacalin, a galactose-binding lectin with the characteristic beta-prism-I fold (Raval et al., 2004). This domain
consists in four-stranded beta-sheets and the lectins with this domain are assembled in a family called Jacalin-related lectins (JRL) (Esch and Schaffrath, 2017).

The prophylactic inoculation (3 days before infection) of the crude extract of A. integrifolia seeds (containing Artin M and jacalin) resulted in the enhanced survival and reduced liver injury of Swiss mice infected with C. albicans. These effects were not observed when mice were treated with jacalin alone. Using the same protocol, the authors showed that the Artin M alone or in combination with jacalin induced a Th1 and Th17 response mediated by dectin-1 and mannose receptors, resulting in a significant increase of TNF-α production, phagocytic and candidacidal activities (Custodio et al., 2011). Similarly, it was demonstrated that Artin M increased the TNF-α production and phagocytic activity of C. albicans by mice macrophages. These actions of Artin M were mediated by dectin-1 and mannose receptors (Loyola et al., 2012).

In addition, Artin M (in both native and recombinant form) also showed efficacy against the infection caused by Paracoccidioides brasiliensis (Coltri et al., 2008). The authors performed an elegant work where they first determined that the best treatment schedule consisted in the subcutaneous administration of Artin M in single dose (0.5 μg of KM in 50 μL of PBS) and 10 days after infection with P. brasiliensis. Mice treated with Artin M displayed reduced levels of yeasts on their lungs and consequently less pulmonary lesions. These effects were induced through production of IL-12 by a TLR-2 dependent mechanism (Coltri et al., 2008).

Cramoll Has Therapeutic Benefits in Mice Infected with Cryptococcus gattii

A recent paper reported the use of the lectin purified from seeds of Cratyli mollis (pCramoll or Cramoll 1,4) for the treatment of mice infected with Cryptococcus gattii. C. mollis is an endemic plant of Caatinga (Brazil semi-arid area), a plant from the Brazilian exclusive biome. pCramoll is a mannose-specific lectin and it has shown several biotechnological applications, including induction of cell proliferation (Maciel et al., 2004; da Silva et al., 2015a), in vitro immunomodulation (de Melo et al., 2010; da Silva et al., 2015b), wound healing (Albuquerque et al., 2017), and anticancer properties (da Cunha et al., 2016). Particularly, the immunomodulatory ability of pCramoll has been demonstrated in an in vivo model of wound healing in immunocompromised mice (de Oliveira Silva et al., 2011) and in experimental infection with Schistosoma mansoni (de Oliveira Silva et al., 2011). Cramoll, however, did not show antimicrobial activity in vitro.

Initially, pCramoll was administered in different concentrations (1, 250, and 500 μg) 1 day before the intratracheal infection with C. gattii. Afterward, every 10 days after infection a new dose of lectin was given to the mice. pCramoll enhanced the mice survival equally in all tested concentrations. When combined with fluconazole (azole antifungal drug), the best results were found for this lectin at 1 μg. pCramoll alone or in combination with fluconazole decreased pulmonary fungal burden of mice. These effects were associated with an increase of inflammatory infiltrate on the lungs, and modulatory action on cytokines levels (down-regulation of IFNγ, IL-6, and IL-10 and up-regulation of IL-17A). The combined treatment of pCramoll and fluconazole also significantly decrease the fungal load in the brain, reducing the morbidity and behavior changes caused by the infection (i.e., neuropsychiatric state, motor behavior, autonomic function, tone and muscle strength, and reflex/sensory function). Moreover, in vitro analysis revealed
that bone marrow-derived macrophages treated with pCramoll were more able to phagocyte \textit{C. gattii}, with higher production of reactive oxygen species, and decreased the intracellular fungal proliferation (Jandú et al., 2017). These findings are summarized in Figure Figure22.

FIGURE 2
An overview of the effects of Cramoll alone or in combination with fluconazole in an experimental cryptococcosis model. (A) \textit{Cryptococcus gattii} provokes tissue damage and organ dysfunction by releasing different virulence factors and inducing an exacerbated immune response. (B) When Cramoll was administrated alone (B) or in combination with fluconazole (C), infected mice exhibited increased ratios of survival and reduced levels of morbidity and behavior alteration. The PDB code for Cramoll structure is 1MVQ.

Go to:

Plant Lectins and Protozoan Infections
Some plant lectins (Jacalin, Artin M, and ScLL) have been also successfully applied against infections caused by protozoan. These lectins were used in infections caused by \textit{Trypanosoma cruzi} (Albuquerque et al., 1999), \textit{Leishmania} spp. (Panunto-Castelo et al., 2001), \textit{Neospora caninum} (Cardoso et al., 2011, 2012), and \textit{Toxoplasma gondii} (de
Souza et al., 2016). In these studies, the lectins were used also as adjuvants in combination to parasite antigens in order to induce a more efficient immunization.

**Jacalin as Adjuvant in *Trypanosoma cruzi* Infection**

The effects of jacalin in the humoral immune response toward *T. cruzi* infection were evaluated using Balb/c mice (Albuquerque et al., 1999). Jacalin is able to modulate cellular and humoral immunity, which makes it a potential candidate for use as an adjuvant compound (Miyamoto et al., 2012; Danella Polli et al., 2016). Initially, the animals were inoculated with *T. cruzi* antigens in the presence or not of Jacalin. The mice submitted to immunization with *T. cruzi* antigens plus Jacalin produced more antibodies (and faster) than animals immunized only with parasite antigens. The efficiency of immunization using *T. cruzi* antigens plus Jacalin was also demonstrated by challenging 1-month-old immunized mice with trypomastigotes. These animals showed reduced levels of parasitemia when compared to non-immunized mice. Similarly, mice immunized with viable *T. cruzi* epimastigotes (at 1.0 × 10⁵ or 1.0 × 10⁶) plus Jacalin produced more antibodies than mice inoculated with parasites alone. However, the combined inoculation of 1.0 × 10⁶ *T. cruzi* epimastigotes plus jacalin resulted in lower levels of parasite after 9 days of infection than animals immunized only with epimastigotes. Jacalin alone did not protected the animals from infection (Albuquerque et al., 1999; Figure Figure3).

![Figure 3](image)

**FIGURE 3**

Application of Jacalin as adjuvant for immunization against *T. cruzi*. (A) Mice were immunized with *T. cruzi* antigens and after 1 month infected with *T. cruzi*. The antigens failed in inducing an efficient protective humoral response. (B) Animal subjected to immunization with jacalin (PDB ID 1JAC) plus *T. cruzi* antigens showed higher antibodies titers and lower parasitemia levels than mice that received only *T. cruzi* antigens.

**Artin M Is a Potent Adjuvant in Leishmaniasis Model**

The evidence that Artin M could be useful to treat protozoan infections was obtained from the ability of this lectin to induce the expression of IL-12p40, which could drive the production of Th1 cytokines instead of the Th2 pattern, typical of unresponsive parasite
infections (Figure 4). The authors performed a combined administration of Artin M and soluble leishmanial antigen (SLA) into the footpad of BALB/c mice. SLA injected animals showed higher levels of IL-4 than the group treated with SLA+Artin M, while the IFN-γ concentration was higher in SLA+Artin M group. The animals treated with Artin M alone or SLA+Artin M were also more resistant to *Leishmania major* infection, and these mice showed smaller lesions than those groups treated with SLA alone or untreated animals (Panunto-Castelo et al., 2001).

**FIGURE 4**

Therapeutic effects of plant lectins in protozoan infections. Experimental exposure of mice to protozoan results in cell damage, tissue destruction, and consequently animal death (A). Lectins can improve protozoan-infected animal survival by increasing production of Th1 cytokines. The induction of pro-inflammatory response leads to a reduction in parasite levels and organ dysfunction (B). The structure of Artin M was obtained from PDB (ID: 1J4U).

Recently, it was shown that Artin M improved the *in vitro* killing of *L. major* by neutrophils through modulation of effector mechanisms, such as enhanced excretion of inflammatory cytokines, reactive oxygen species, and neutrophil elastase and myeloperoxidase. In addition, the infected-neutrophils treated with Artin M did not form neutrophil extracellular traps and showed shorter life span than untreated infected cells, both characteristics that may favor the maintenance of host tissue integrity (Ricci-Azevedo et al., 2016).

Artin M was also effective as an adjuvant of SLA in immunization against *Leishmania amazonensis* (Teixeira et al., 2006). Artin M+SLA administration reduced the parasite amounts in the footpad of mice infected with *L. amazonensis* 15 days after immunization, although the lesion size was not reduced. Mice treated only with Artin M showed smaller lesion and decreased parasite load in relation to the untreated group (but the levels of parasites were not smaller than Artin M+SLA group). Other pro-inflammatory plant lectins (ConBr and PAA purified from *Pisum arvense*) were not able to inhibit the lesion
size in mice infected with *L. amazonensis*, even when inoculated in combination with SLA. However, the association of ConBr and SLA resulted in smaller number of parasites in the footpad of immunized animals when compared to the controls (Teixeira et al., 2006).

**ScLL and Prophylactic Treatment of *L. amazonensis***

The lectin obtained from leaves latex of *Synadenium carinatum* (ScLL) has also shown protective effects in a murine model of leishmaniasis induced by *L. amazonensis*. In this study, BALB/c mice received three doses of ScLL (10, 50, or 100 μg/animal) in the presence or not of SLA (25 μg/animal) with intervals of 15 days. Three days after this immunization, the animals were infected with *L. amazonensis* promastigotes in their left footpad. When administrated alone at 100 μg/animal, ScLL were more effective than when associated with SLA (as shown by reduction of lesion size and parasite load). Thus, this lectin showed a better potential as prophylactic agent than as adjuvant. The mice treated with SLA also showed higher levels of IgG2a and Th1 cytokine expression (IFN-γ, IL-12, and TNF-α) (Afonso-Cardoso et al., 2007). *In vitro* cell-based analysis showed that ScLL reduced the association of macrophages and *L. amazonensis*, inducing the production of pro-inflammatory cytokines (IL-1, IL-12, and TNF-α) in a nitric oxide independent pathway (Afonso-Cardoso et al., 2011).

**Adjuvant Properties of Artin M, Jacalin, and ScLL in Experimental Neosporosis**

*Neospora caninum* (Apicomplexa), etiologic agent of neosporosis, is a prevalent intracellular parasite associated with cases of abortion in cattle and neuromuscular disease in dogs (Donahoe et al., 2015). The potential adjuvant actions of Artin M, Jacalin, and ScLL have been evaluated in murine models of neosporosis. In the first report, C57BL/6 mice received (subcutaneously) three doses with 2-week intervals of *N. caninum* lysate antigen (NLA; 25 μg/animal) associated with Artin M (1 μg/animal) or Jacalin (100 μg/animal). Animals immunized with Artin M+NLA showed higher levels of specific antibodies against *N. caninum* (IgG, IgG1, and IgG2a) than all others groups in all times evaluated (15, 30, and 45 days after immunization). The association of Jacalin and NLA also enhanced the levels of total IgG in relation to animals immunized with NLA alone in all times, however, the levels of IgG1 were only higher until 30 days after immunization. Animals immunized with Jacalin and NLA showed similar levels of IgG2 than NLA group. The mice were then infected with lethal doses of *N. caninum* tachyzoites 60 days after immunization. Artin M+NLA combination resulted in 86% of protection, while the other immunized groups (NLA+JAC, NLA, Artin M, or JAC) were partially protected. In addition, Artin M+NLA reduced the number of parasites in the brain and induced a more robust inflammatory profile. The results highlight that Artin M has more potential to be used as adjuvant for neosporosis than Jacalin (Cardoso et al., 2011).

Cardoso et al. (2012) demonstrated the adjuvant and immunomodulatory effects of ScLL in a similar work. The authors showed that C57BL/6 mice dendritic cells produced inflammatory cytokines when treated with NLA+ScLL or ScLL alone. NLA (25 μg/animal) associated with ScLL (1 μg/animal) were inoculated in C57BL/6 mice three time for 45 days. The animals that received NLA + ScLL produced higher levels of IgG and IgG1 than the NLAimmunized mice. The NLA+ScLL and ScLL groups were also
more resistant to infection by *N. caninum* tachyzoites (which occurred 60 days after the last immunization) (Cardoso et al., 2012).

**Artin M and ScLL for Therapy of Acute Toxoplasmosis**

Recently, the therapeutic properties of both Artin M and ScLL were studied in a model of murine toxoplasmosis. For this, C57BL/6 mice were orally infected with cysts of *T. gondii*, and treated intraperitoneally for 6 days with ScLL (50 μg), Artin M (1 μg), or ScLL (50 μg) plus Artin M (1 μg). The treatment with ScLL was more efficient, resulting in 100% survival, while 60% of the Artin M + ScLL-treated animals and only 40% of Artin M-treated group survived. The best results obtained with ScLL alone are related to its capacity to induce the production of Th1 cytokines (IL-2, IFN-γ, and IL-6) resulting in reduced levels of parasite in the brain (de Souza et al., 2016). Other study showed the action of eutirucallin on the *in vitro* infection of human foreskin fibroblasts (HFF) by *T. gondii* (Palharini et al., 2017). Eutirucallin is a RIP-2 type lectin obtained from the latex of *Euphorbia tirucalli*, which also displays immunostimulatory action (increasing neutrophils migration and release of NO, IL12p40, and TNF-α by peritoneal macrophages) (Santana et al., 2014). Eutirucallin inhibited infection and intracellular replication of *T. gondii* with IC50 of 173.2 and 133.3 μg/mL, respectively (Palharini et al., 2017).

**Conclusion and Perspectives**

The high immunomodulatory abilities of plant lectins were proven efficient to combat microbial infections in different experimental models. Depending on the type of lectin and the kind of infection, the lectin showed better prophylactic or therapeutic behavior. As inductors of Th1 response, some lectins were used as adjuvant agents. These immunotherapeutic studies have also improved our knowledge about the pathogen–immunity relationship, and could be helpful to provide insights for the development of new therapeutic strategies. All these successful examples of plant lectins encourage the study of others lectins with immunomodulatory capabilities for the treatment of infectious diseases. However, it is always important to remind that the possible adverse effects (for example, TNF-α-mediated hepatitis, renal and intestinal injury) should be evaluated before the clinical application of these plant lectins. The side effects depend on type of lectin, dose, and administration route. To the best of our knowledge, the anti-infective effects of plant lectins have not been clinically evaluated in humans (although some lectins have been tested in clinical trials for cancer therapy).

Another challenge is the purification yields that for some lectins could not be suitable for large-scale production. The advances in protein engineering (recombinant protein production, structure–function improvement) and drug delivery technologies (liposomes, microcapsules, etc.) may improve the protein production, stability, and their pharmacokinetics properties (delivery, bioavailability, controlled release, and targetability). These actions may result in enhanced therapeutic index and may reduce likely side effects. Furthermore, the combination of *in silico* approaches and analytical tools for protein have provided more insight in lectin and ligand interactions. In summary, these stimulating research data pave the way for the future use of plant lectin as immunomodulatory agents to combat microbial infections.
Author Contributions
JJ, RMN, AZ, EdS, MB, MdSC, and LdS: Contributed to conception, design, and critically revised the manuscript. All authors gave final approval and agree to be accountable for all aspects of the work.

Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments
The authors would like to express their gratitude to the following Brazilian agencies: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo à Pesquisa e Desenvolvimento Científico do Maranhão (FAPEMA), and Fundação de Amparo à Ciência do Estado de Pernambuco (FACEPE).

References
1. Afonso-Cardoso S. R., Rodrigues F. H., Gomes M. A., Silva A. G., Rocha A., Guimaraes A. H., et al. (2007). Protective effect of lectin from Synadenium carinatum on Leishmania amazonensis infection in BALB/c mice. Korean J. Parasitol. 45 255–266. 10.3347/kjp.2007.45.4.255 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
2. Afonso-Cardoso S. R., Silva C. V., Ferreira M. S., Souza M. A. (2011). Effect of the Synadenium carinatum latex lectin (ScLL) on Leishmania (Leishmania) amazonensis infection in murine macrophages. Exp. Parasitol. 128 61–67. 10.1016/j.exppara.2011.02.006 [PubMed] [CrossRef] [Google Scholar]
3. Albuquerque D. A., Martins G. A., Campos-Neto A., Silva J. S. (1999). The adjuvant effect of jacalin on the mouse humoral immune response to trinitrophenyl and Trypanosoma cruzi. Immunol. Lett. 68 375–381. 10.1016/S0165-2478(99)00079-6 [PubMed] [CrossRef] [Google Scholar]
4. Albuquerque P. B. S., Soares P. A. G., Aragao-Neto A. C., Albuquerque G. S., Silva L. C. N., Lima-Ribeiro M. H. M., et al. (2017). Healing activity evaluation of the galactomannan film obtained from Cassia grandis seeds with immobilized Cratylia mollis seed lectin. Int. J. Biol. Macromol. 102 749–757. 10.1016/j.ijbiomac.2017.04.064 [PubMed] [CrossRef] [Google Scholar]
5. Aminov R. (2016). History of antimicrobial drug discovery - Major classes and health impact. Biochem. Pharmacol. 133 4–19. 10.1016/j.bcp.2016.10.001 [PubMed] [CrossRef] [Google Scholar]
6. Antachopoulos C., Walsh T. J. (2012). Immunotherapy of Cryptococcus infections. Clin. Microbiol. Infect. 18 126–133. 10.1111/j.1469-0691.2011.03741.x [PubMed] [CrossRef] [Google Scholar]

7. Armstrong-James D., Harrison T. S. (2012). Immunotherapy for fungal infections. Curr. Opin. Microbiol. 15 434–439. 10.1016/j.mib.2012.06.001 [PubMed] [CrossRef] [Google Scholar]

8. Badiie P., Hashemizadeh Z. (2014). Opportunistic invasive fungal infections: diagnosis & clinical management. Indian J. Med. Res. 139 195–204. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

9. Batista J., Ralph M. T., Vaz R. V., Souza P., Silva A. B., Nascimento D., et al. (2017). Plant lectins ConBr and CFL modulate expression toll-like receptors, pro-inflammatory cytokines and reduce the bacterial burden in macrophages infected with Salmonella enterica serovar Typhimurium. Phytomedicine 25 52–60. 10.1016/j.phymed.2016.12.005 [PubMed] [CrossRef] [Google Scholar]

10. Blair J. M., Webber M. A., Baylay A. J., Ogbolu D. O., Piddock L. J. (2015). Molecular mechanisms of antibiotic resistance. Nat. Rev. Microbiol. 13 42–51. 10.1038/nrmicro3380 [PubMed] [CrossRef] [Google Scholar]

11. Camplesi M. J., Silva H. M., Arantes A. M., Costa C. R., Ataides F. S., Silva T. C., et al. (2017). Invasive fungal infection in patients with hematologic disorders in a Brazilian tertiary care hospital. Rev. Soc. Bras. Med. Trop. 50 80–85. 10.1590/0037-8682-0191-2016 [PubMed] [CrossRef] [Google Scholar]

12. Cardoso M. R., Mota C. M., Ribeiro D. P., Noleto P. G., Andrade W. B., Souza M. A., et al. (2012). Adjuvant and immunostimulatory effects of a D-galactose-binding lectin from Synadenium carinatum latex (ScLL) in the mouse model of vaccination against neosporosis. Vet. Res. 43:76 10.1186/1297-9716-43-76 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

13. Cardoso M. R., Mota C. M., Ribeiro D. P., Santiago F. M., Carvalho J. V., Araujo E. C., et al. (2011). ArtinM, a D-mannose-binding lectin from Artocarpus integrifolia, plays a potent adjuvant and immunostimulatory role in immunization against Neospora caninum. Vaccine 29 9183–9193. 10.1016/j.vaccine.2011.09.136 [PubMed] [CrossRef] [Google Scholar]

14. Chaves M. M., Canetti C., Coutinho-Silva R. (2016). Crosstalk between purinergic receptors and lipid mediators in leishmaniasis. Parasit. Vectors 9 489 10.1186/s13071-016-1781-1 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

15. Chowdhary A., Sharma C., Hagen F., Meis J. F. (2014). Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms. Future Microbiol. 9 697–711. 10.2217/fmb.14.27 [PubMed] [CrossRef] [Google Scholar]

16. Coelho L. C., Silva P. M., Lima V. L., Pontual E. V., Paiva P. M., Napoleao T. H., et al. (2017). Lectins, interconnecting proteins with biotechnological/pharmacological and therapeutic applications. Evid. Based Complement. Alternat. Med. 2017:1594074 10.1155/2017/1594074 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

17. Coltri K. C., Oliveira L. L., Pinzan C. F., Vendruscolo P. E., Martinez R., Goldman M. H., et al. (2008). Therapeutic administration of KM + lectin protects mice against Paracoccidioides brasiliensis infection via interleukin-12 production.
in a toll-like receptor 2-dependent mechanism. *Am. J. Pathol.* 173 423–432. 10.2353/ajpath.2008.080126 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

18. Custodio L. A., Loyola W., Conchon-Costa I., Da Silva Quirino G. F., Felipe I. (2011). Protective effect of Artin M from extract of *Artocarpus integrifolia* seeds by Th1 and Th17 immune response on the course of infection by *Candida albicans*. *Int. Immunopharmacol.* 11 1510–1515. 10.1016/j.intimp.2011.05.005 [PubMed] [CrossRef] [Google Scholar]

19. Czaplewski L., Bax R., Clokie M., Dawson M., Fairhead H., Fischetti V. A., et al. (2016). Alternatives to antibiotics—a pipeline portfolio review. *Lancet Infect. Dis.* 16 239–251. 10.1016/S1473-3099(15)00466-1 [PubMed] [CrossRef] [Google Scholar]

20. da Cunha C. R., Da Silva L. C., Almeida F. J., Ferraz M. S., Varejao N., Cartaxo M. F., et al. (2016). Encapsulation into stealth liposomes enhances the antitumor action of recombinant *Cratyli mollis* lectin expressed in *Escherichia coli*. *Front. Microbiol.* 7:1355 10.3389/fmicb.2016.01355 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

21. da Silva L. C., Alves N. M., De Castro M. C., Higino T. M., Da Cunha C. R., Pereira V. R., et al. (2015a). pCramoll and rCramoll as new preventive agents against the oxidative dysfunction induced by hydrogen peroxide. *Oxid. Med. Cell. Longev.* 2015:520872 10.1155/2015/520872 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

22. da Silva L. C., Alves N. M., De Castro M. C., Pereira V. R., Da Paz N. V., Coelho L. C., et al. (2015b). Immunomodulatory effects of pCramoll and rCramoll on peritoneal exudate cells (PECs) infected and non-infected with *Staphylococcus aureus*. *Int. J. Biol. Macromol.* 72 848–854. [PubMed] [Google Scholar]

23. da Silva L. C., Correia M. T. (2014). Plant lectins and Toll-like receptors: implications for therapy of microbial infections. *Front. Microbiol.* 5:20 10.3389/fmicb.2014.00020 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

24. Danella Polli C., Pereira Ruas L., Chain Veronez L., Herrero Geraldino T., Rossetto De Morais F., Roque-Barreirae M. C., et al. (2016). Jacalin-activated macrophages exhibit an antitumor phenotype. *Biomed Res. Int.* 2016:2925657 10.1155/2016/2925657 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

25. Datta K., Hamad M. (2015). Immunotherapy of fungal infections. *Immunol. Invest.* 44 738–776. 10.3109/08820139.2015.1093913 [PubMed] [CrossRef] [Google Scholar]

26. Davies J., Davies D. (2010). Origins and evolution of antibiotic resistance. *Microbiol. Mol. Biol. Rev.* 74 417–433. 10.1128/MMBR.00016-10 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

27. de Macedo P. M., Almeida-Paes R., De Medeiros Muniz M., Oliveira M. M., Zancope-Oliveira R. M., Costa R. L., et al. (2016). *Paracoccidioides brasiliensis* PS2: first autochthonous paracoccioidiomycosis case report in Rio de Janeiro, Brazil, and literature review. *Mycopathologia* 181 701–708. 10.1007/s11046-016-0015-6 [PubMed] [CrossRef] [Google Scholar]

28. de Melo C. M., De Castro M. C., De Oliveira A. P., Gomes F. O., Pereira V. R., Correia M. T., et al. (2010). Immunomodulatory response of Cramoll 1,4 lectin on
experimental lymphocytes. *Phytother. Res.* 24 1631–1636. 10.1002/ptr.3156 [PubMed] [CrossRef] [Google Scholar]

29. de Oliveira H. C., Assato P. A., Marcos C. M., Scorzoni L., De Paula E. S. A. C., Da Silva Jde F., et al. (2015). Paracoccidioides-host interaction: an overview on recent advances in the paracoccidioidomycosis. *Front. Microbiol.* 6:1319 10.3389/fmicb.2015.01319 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

30. de Oliveira Figueiroa E., Da Cunha C. R. A., Albuquerque P. B. S., De Paula R. A., Aranda-Souza M. A., Da Silva M. A., et al. (2017). Lectin-carbohydrate interactions: implications for the development of new anticancer agents. *Curr. Med. Chem.* 10.2174/0929867324666170523110400 [Epub ahead of print]. [PubMed] [CrossRef] [Google Scholar]

31. de Oliveira Silva F., Das Neves Santos P., De Melo C. M., Teixeira E. H., De Sousa Cavada B., Arruda F. V., et al. (2011). Immunostimulatory activity of ConBr: a focus on splenocyte proliferation and proliferative cytokine secretion. *Cell Tissue Res.* 346 237–244. 10.1007/s00441-011-1239-x [PubMed] [CrossRef] [Google Scholar]

32. de Souza L. P. F., Ramos E. L., Santana S. S., Silva M. V., Santiago F. M., Mineo T. W., et al. (2016). Lectins from *Synadenium carinatum* (ScLL) and *Artocarpus heterophyllus* (ArtinM) are able to induce beneficial immunomodulatory effects in a murine model for treatment of *Toxoplasma gondii* infection. *Front. Cell Infect. Microbiol.* 6:164 10.3389/fcimb.2016.00164 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

33. Dias Rde O., Machado Ldos S., Migliolo L., Franco O. L. (2015). Insights into animal and plant lectins with antimicrobial activities. *Molecules* 20 519–541. 10.3390/molecules20010519 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

34. Donahoe S. L., Lindsay S. A., Krockenberger M., Phalen D., Slapeta J. (2015). A review of neosporosis and pathologic findings of *Neospora caninum* infection in wildlife. *Int. J. Parasitol. Parasites Wildl.* 4 216–238. 10.1016/j.ijppaw.2015.04.002 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

35. Enoch D. A., Yang H., Aliyu S. H., Micallef C. (2017). The changing epidemiology of invasive fungal infections. *Methods Mol. Biol.* 1508 17–65. 10.1007/978-1-4939-6515-1_2 [PubMed] [CrossRef] [Google Scholar]

36. Esch L., Schaffrath U. (2017). An update on jacalin-like lectins and their role in plant defense. *Int. J. Mol. Sci.* 18:E1592 10.3390/ijms18071592 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

37. Fairlamb A. H., Gow N. A., Matthews K. R., Waters A. P. (2016). Drug resistance in eukaryotic microorganisms. *Nat Microbiol* 1 16092 10.1038/nmicrobiol.2016.92 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

38. Fu J., Ding Y., Wei B., Wang L., Xu S., Qin P., et al. (2017). Epidemiology of *Candida albicans* and non-*C. albicans* of neonatal candidemia at a tertiary care hospital in western China. *BMC Infect. Dis.* 17:329 10.1186/s12879-017-2423-8 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

39. Fura J. M., Sarkar S., Pidgeon S. E., Pires M. M. (2017). Combatting bacterial pathogens with immunomodulation and infection tolerance strategies. *Curr. Top.
40. Ganiko L., Martins A. R., Freymuller E., Mortara R. A., Roque-Barreira M. C. (2005). Lectin KM+-induced neutrophil haptotaxis involves binding to laminin. *Biochim. Biophys. Acta* 1721 152–163. 10.1016/j.bbagen.2004.10.012 [PubMed] [CrossRef] [Google Scholar]

41. Gomes P. S., Bhardwaj J., Rivera-Correa J., Freire-De-Lima C. G., Morrot A. (2016). Immune escape strategies of malaria parasites. *Front. Microbiol.* 7:1617 10.3389/fmicb.2016.01617 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

42. Goncalves S. S., Souza A. C., Chowdhary A., Meis J. F., Colombo A. L. (2016). Epidemiology and molecular mechanisms of antifungal resistance in *Candida* and *Aspergillus*. *Mycoses* 10.1111/myc.12469 [Epub ahead of print]. [PubMed] [CrossRef] [Google Scholar]

43. Gullo F. P., Rossi S. A., Sardi Jde C., Teodoro V. L., Mendes-Giannini M. J., Fusco-Almeida A. M. (2013). Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment. *Eur. J. Clin. Microbiol. Infect. Dis.* 32 1377–1391. 10.1007/s10096-013-1915-8 [PubMed] [CrossRef] [Google Scholar]

44. Hall C. W., Mah T. F. (2017). Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria. *FEMS Microbiol. Rev.* 41 276–301. 10.1093/femsre/fux010 [PubMed] [CrossRef] [Google Scholar]

45. Hancock R. E., Nijnik A., Philpott D. J. (2012). Modulating immunity as a therapy for bacterial infections. *Nat. Rev. Microbiol.* 10 243–254. 10.1038/nrmicro2745 [PubMed] [CrossRef] [Google Scholar]

46. Holmes A. H., Moore L. S., Sundsfjord A., Steinbakk M., Regmi S., Karkey A., et al. (2016). Understanding the mechanisms and drivers of antimicrobial resistance. *Lancet* 387 176–187. 10.1016/S0140-6736(15)00473-0 [PubMed] [CrossRef] [Google Scholar]

47. Hwang I. S., Hwang B. K. (2011). The pepper mannose-binding lectin gene CaMBL1 is required to regulate cell death and defense responses to microbial pathogens. *Plant Physiol.* 155 447–463. 10.1104/pp.110.164848 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

48. Islam B., Khan A. U. (2012). “Lectins: to combat infections,” in *Protein Purification*, ed. Ahmad R. (Rijeka: InTech; ). 10.5772/30212 [CrossRef] [Google Scholar]

49. Jandú J. J. B., Costa M. C. D., Santos J. R., Andrade F. M. D., Magalhães T. F. F., Gomes A. G., et al. (2017). Treatment with pCramoll alone and in combination with fluconazole provides therapeutic benefits in *C. gattii* infected mice. *Front. Cell Infect. Microbiol.* 7:211 10.3389/fcimb.2017.00211 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

50. Kaur R., Mehra B., Dhakad M. S., Goyal R., Bhatta P., Dewan R. (2017). Fungal opportunistic pneumonias in HIV/AIDS patients: an Indian tertiary care experience. *J. Clin. Diagn. Res.* 11 DC14–DC19. 10.7860/JCDR/2017/24219.9277 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

51. Kim N. H., Lee D. H., Choi Du S., Hwang B. K. (2015). The pepper GNA-related lectin and PAN domain protein gene, CaGLP1, is required for plant cell death and
defense signaling during bacterial infection. *Plant Sci.* 241 307–315. [10.1016/j.plantsci.2015.07.003](https://doi.org/10.1016/j.plantsci.2015.07.003) [PubMed] [CrossRef] [Google Scholar]

52. Ko K. S. (2016). The contribution of capsule polysaccharide genes to virulence of *Klebsiella pneumoniae*. *Virulence* 8 485–486. [10.1080/21505594.2016.1240862](https://doi.org/10.1080/21505594.2016.1240862) [PMC free article] [PubMed] [CrossRef] [Google Scholar]

53. Komath S. S., Kavitha M., Swamy M. J. (2006). Beyond carbohydrate binding: new directions in plant lectin research. *Org. Biomol. Chem.* 4 973–988. [10.1039/b515446d](https://doi.org/10.1039/b515446d) [PubMed] [CrossRef] [Google Scholar]

54. Kuo C. F., Wang Y. H., Lei H. Y., Wang C. H., Tsao N. (2007). Concanavalin A protects mice from a lethal inoculation of intragastric *Klebsiella pneumoniae* and reduces the induced liver damage. *Antimicrob. Agents Chemother.* 51 3122–3130. [10.1128/AAC.01379-06](https://doi.org/10.1128/AAC.01379-06) [PMC free article] [PubMed] [CrossRef] [Google Scholar]

55. Laxminarayan R., Matsoso P., Pant S., Brower C., Rottingen J. A., Klugman K., et al. (2016). Access to effective antimicrobials: a worldwide challenge. *Lancet* 387 168–175. [10.1016/S0140-6736(15)00474-2](https://doi.org/10.1016/S0140-6736(15)00474-2) [PubMed] [CrossRef] [Google Scholar]

56. Loyola W., Custodio L. A., Felipe I., Conchon-Costa I., Carvalho P. G., Quirino G. F., et al. (2012). Artin M enhances TNF-alpha production and phagocytosis of *Candida albicans* mediated by dectin-1 and mannose receptors. *Int. Immunopharmacol.* 12 378–383. [10.1016/j.intimp.2011.12.010](https://doi.org/10.1016/j.intimp.2011.12.010) [PubMed] [CrossRef] [Google Scholar]

57. Loyola W., Gaziri D. A., Gaziri L. C., Felipe I. (2002). Concanavalin A enhances phagocytosis and killing of *Candida albicans* by mice peritoneal neutrophils and macrophages. *FEMS Immunol. Med. Microbiol.* 33 201–208. [10.1111/j.1574-695X.2002.tb00591.x](https://doi.org/10.1111/j.1574-695X.2002.tb00591.x) [PubMed] [CrossRef] [Google Scholar]

58. Maciel E. V., Araujo-Filho V. S., Nakazawa M., Gomes Y. M., Coelho L. C., Correia M. T. (2004). Mitogenic activity of *Cratylia mollis* lectin on human lymphocytes. *Biologicals* 32 57–60. [10.1016/j.biologicals.2003.12.001](https://doi.org/10.1016/j.biologicals.2003.12.001) [PubMed] [CrossRef] [Google Scholar]

59. Malachowski A. N., Yosri M., Park G., Bahn Y. S., He Y., Olszewski M. A. (2016). Systemic approach to virulence gene network analysis for gaining new insight into cryptococcal virulence. *Front. Microbiol.* 7:1652 10.3389/fmicb.2016.01652 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

60. McMullan B. J., Sorrell T. C., Chen S. C. (2013). *Cryptococcus gattii* infections: contemporary aspects of epidemiology, clinical manifestations and management of infection. *Future Microbiol.* 8 1613–1631. [10.2217/fmb.13.123](https://doi.org/10.2217/fmb.13.123) [PubMed] [CrossRef] [Google Scholar]

61. Miyamoto K., Chiba T., Shinohara N., Nagata Y., Asakawa N., Kato S., et al. (2012). Jacalin regulates IgA production by peripheral blood mononuclear cells. *Immunotherapy* 4 1823–1834. [10.2217/imt.12.125](https://doi.org/10.2217/imt.12.125) [PubMed] [CrossRef] [Google Scholar]

62. Morens D. M., Fauci A. S. (2013). Emerging infectious diseases: threats to human health and global stability. *PLOS Pathog.* 9:e1003467 10.1371/journal.ppat.1003467 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
63. Moresco T. R., Gaziri L. C., Yasumoto Y., Felipe I. (2002). Phagocytic and candidacidal activities of macrophages from suckling and adult mice pretreated with concanavalin-A. *Med. Mycol.* 40:393–397. 10.1080/mmy.40.4.393.397 [PubMed] [CrossRef] [Google Scholar]

64. Palharini J. G., Richter A. C., Silva M. F., Ferreira F. B., Pirovani C. P., Naves K. S. C., et al. (2017). Eutirucallin: a lectin with antitumor and antimicrobial properties. *Front. Cell Infect. Microbiol.* 7:136 10.3389/fcimb.2017.00136 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

65. Panunto-Castelo A., Souza M. A., Roque-Barreira M. C., Silva J. S. (2001). KM+, a lectin from *Artocarpus integrifolia*, induces IL-12 p40 production by macrophages and switches from type 2 to type 1 cell-mediated immunity against *Leishmania major* antigens, resulting in BALB/c mice resistance to infection. *Glycobiology* 11:1035–1042. 10.1093/glycob/11.12.1035 [PubMed] [CrossRef] [Google Scholar]

66. Pereira-da-Silva G., Carvalho F. C., Roque-Barreir M. C. (2012). Neutrophil activation induced by plant lectins: modulation of inflammatory processes. *Inflamm. Allergy Drug Targets* 11:433–441. 10.2174/187152812803589985 [PubMed] [CrossRef] [Google Scholar]

67. Posch W., Steger M., Wilflingseder D., Lass-Florl C. (2017). Promising immunotherapy against fungal diseases. *Expert Opin. Biol. Ther.* 17:861–870. 10.1080/14712598.2017 [PubMed] [CrossRef] [Google Scholar]

68. Raja S. B., Murali M. R., Kumar N. K., Devaraj S. N. (2011). Isolation and partial characterisation of a novel lectin from *Aegle marmelos* fruit and its effect on adherence and invasion of Shigellae to HT29 cells. *PLOS ONE* 6:e16231 10.1371/journal.pone.0016231 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

69. Raval S., Gowda S. B., Singh D. D., Chandra N. R. (2004). A database analysis of jacalin-like lectins: sequence-structure-function relationships. *Glycobiology* 14:1247–1263. 10.1093/glycob/cwh140 [PubMed] [CrossRef] [Google Scholar]

70. Ricci-Azevedo R., Oliveira A. F., Conrado M. C., Carvalho F. C., Roque-Barreira M. C. (2016). Neutrophils contribute to the protection conferred by ArtinM against intracellular pathogens: a study on *Leishmania major*. *PLOS Negl. Trop. Dis.* 10:e0004609 10.1371/journal.pntd.0004609 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

71. Rogalski M. A., Gowler C. D., Shaw C. L., Hufbauer R. A., Duffy M. A. (2017). Human drivers of ecological and evolutionary dynamics in emerging and disappearing infectious disease systems. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* 372 20160043 10.1098/rstb.2016.0043 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

72. Safdar A., Hanna H. A., Boktour M., Kontoyiannis D. P., Hachem R., Lichtiger B., et al. (2004). Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of *Candida* species bloodstream infections. *Cancer* 101:2859–2865. 10.1002/cncr.20710 [PubMed] [CrossRef] [Google Scholar]

73. Sands P., Mundaca-Shah C., Dzau V. J. (2016). The neglected dimension of global security—A framework for countering infectious-disease crises. *N. Engl. J.*
74. Santana S. S., Gennari-Cardoso M. L., Carvalho F. C., Roque-Barreira M. C., Santiago Ada S., Alvim F. C., et al. (2014). Eutirucallin, a RIP-2 type lectin from the latex of *Euphorbia tirucalli* L. presents proinflammatory properties. *PLOS ONE* 9:e88422 10.1371/journal.pone.0088422 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

75. Scorzoni L., De Paula E. S. A. C., Marcos C. M., Assato P. A., De Melo W. C., De Oliveira H. C., et al. (2017). Antifungal therapy: new advances in the understanding and treatment of mycosis. *Front. Microbiol.* 8:36 10.3389/fmicb.2017.00036 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

76. Sha S., Shi X., Deng G., Chen L., Xin Y., Ma Y. (2017). *Mycobacterium tuberculosis* Rv1987 induces Th2 immune responses and enhances *Mycobacterium smegmatis* survival in mice. *Microbiol. Res.* 197 74–80. 10.1016/j.micres.2017.01.004 [PubMed] [CrossRef] [Google Scholar]

77. Silva A. F., Matos M. P., Ralph M. T., Silva D. L., De Alencar N. M., Ramos M. V., et al. (2016a). Comparison of immunomodulatory properties of mannose-binding lectins from *Canavalia brasiliensis* and *Cratylia argentea* in a mice model of *Salmonella* infection. *Int. Immunopharmacol.* 31 233–238. 10.1016/j.intimp.2015.12.036 [PubMed] [CrossRef] [Google Scholar]

78. Silva P. M., Napoleão T. H., Silva L. C. P. B. B., Fortes D. T. O., Lima T. A., Zingali R. B., et al. (2016b). The juicy sarcotesta of *Punica granatum* contains a lectin that affects growth, survival as well as adherence and invasive capacities of human pathogenic bacteria. *J. Funct. Foods* 27 695–702. 10.1016/j.jff.2016.10.015 [CrossRef] [Google Scholar]

79. Sodhi A., Tarang S., Keshewani V. (2007). Concanavalin A induced expression of Toll-like receptors in murine peritoneal macrophages in vitro. *Int. Immunopharmacol.* 7 454–463. 10.1016/j.intimp.2006.11.014 [PubMed] [CrossRef] [Google Scholar]

80. Souza M. A., Carvalho F. C., Ruas L. P., Ricci-Azevedo R., Roque-Barreira M. C. (2013). The immunomodulatory effect of plant lectins: a review with emphasis on ArtinM properties. *Glycoconjug. J.* 30 641–657. 10.1007/s10719-012-9464-4 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

81. Stuehler C., Khanna N., Bozza S., Zelante T., Moretti S., Kruhm M., et al. (2011). Cross-protective TH1 immunity against *Aspergillus fumigatus* and *Candida albicans*. *Blood* 117 5881–5891. 10.1182/blood-2010-12-325084 [PubMed] [CrossRef] [Google Scholar]

82. Sungkanuparph S., Savetamornkul C., Pattanapongpaiboon W. (2017). Primary prophylaxis for cryptococcosis with fluconazole in human immunodeficiency virus-infected patients with CD4 T-cell counts <100 cells/μL and receiving antiretroviral therapy. *Clin. Infect. Dis* 64 967–970. 10.1093/cid/cix036 [PubMed] [CrossRef] [Google Scholar]

83. Teixeira C. R., Cavassani K. A., Gomes R. B., Teixeira M. J., Roque-Barreira M. C., Cavada B. S., et al. (2006). Potential of KM+ lectin in immunization against *Leishmania amazonensis* infection. *Vaccine* 24 3001–3008. 10.1016/j.vaccine.2005.11.067 [PubMed] [CrossRef] [Google Scholar]
84. Unitt J., Hornigold D. (2011). Plant lectins are novel Toll-like receptor agonists. *Biochem. Pharmacol.* 81 1324–1328. 10.1016/j.bcp.2011.03.010 [PubMed] [CrossRef] [Google Scholar]

85. Vaezi A., Fakhim H., Khodavaisy S., Alizadeh A., Nazeri M., Soleimani A., et al. (2017). Epidemiological and mycological characteristics of candidemia in Iran: a systematic review and meta-analysis. *J. Mycol. Med.* 27 146–152. 10.1016/j.mycmed.2017.02.007 [PubMed] [CrossRef] [Google Scholar]

86. Van Acker H., Van Dijck P., Coenye T. (2014). Molecular mechanisms of antimicrobial tolerance and resistance in bacterial and fungal biofilms. *Trends Microbiol.* 22 326–333. 10.1016/j.tim.2014.02.001 [PubMed] [CrossRef] [Google Scholar]

87. Woyciechowsky T. G., Dalcin D. C., Dos Santos J. W., Michel G. T. (2011). Paracoccidioidomycosis induced by immunosuppressive drugs in a patient with rheumatoid arthritis and bone sarcoma: case report and review of the literature. *Mycopathologia* 172 77–81. 10.1007/s11046-011-9403-0 [PubMed] [CrossRef] [Google Scholar]

88. Wu H., Li D., Zhou H., Sun Y., Guo L., Shen D. (2017). Bacteremia and other body site infection caused by hypervirulent and classic *Klebsiella pneumoniae*. *Microb. Pathog.* 104 254–262. 10.1016/j.micpath.2017.01.049 [PubMed] [CrossRef] [Google Scholar]